MGMT and neoplasm: In addition, immune cell infiltration, immune checkpoint gene expression, immune subtype identification, tumor mutation profile, tumor stemness indices, O6-methylguanine DNA methyltransferase (MGMT) methylation, and immunotherapy response biomarkers were analyzed between the low- and high-risk cohorts to examine the possible mechanisms and pathways associated with FPRGs, laying the groundwork for determining the beneficiaries of immunotherapy.